Literature DB >> 11716043

Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age.

P E Voutilainen1, M M Multanen, A K Leppäniemi, C H Haglund, R K Haapiainen, K O Franssila.   

Abstract

Papillary thyroid carcinoma (PTC) is a malignancy that has good prognosis especially among patients up to 45 years of age; about half of the patients are female and of childbearing age. Lymph node recurrence (LNR) occurs in 10%-14% of patients but is considered to be associated with relatively good prognosis. The purpose of this study was to estimate the association between patient age at primary operation, and the behavior of the disease after LNR. Between 1967 and 1994, 495 patients underwent surgery for primary PTC at the Department of Surgery, Helsinki University Central Hospital. There were 391 (79.0%) women and 104 (21.0%) men with a mean age of 44.5 years (range, 10.8-85.4 years). Fifty-eight patients in whom LNR was the first clinical sign of persistent disease after complete clinical response to primary treatment were included in this series. At the time of primary operation, 37 (64.3%) of the 58 patients who developed LNR were younger than 45 years of age and 21 patients were older. The mean times to LNR in these groups were 42.0 months (range, 3.0-194.5 months) and 49.0 months (range, 3.6-209.0 months) respectively. Carcinoma-specific 5-year survival after LNR was 100% (95% confidence interval [CI] 88.8%-100.0%) in patients ages up to 45 years and 61.1% (40.5%-82.8%) in older patients; 10-year survival rates were 100%, and 41.3% (p < 0.0001), respectively. Relative survival at 10 years was 98.6% for patients ages up to 45 years and 42.6% for older patients (p = 0.0014). Using the Cox model it was shown that development of LNR after primary treatment has an independent highly significant negative effect on survival (p < 0.001) in patients over 45 years of age. Prognosis of PTC even after LNR on patients ages up to 45 years at the time of the primary operation is almost parallel to the normal reference population, but in patients over 45 years of age the prognosis is relatively poor.

Entities:  

Mesh:

Year:  2001        PMID: 11716043     DOI: 10.1089/105072501753211028

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  25 in total

1.  Pattern of initial metastasis in the cervical lymph node from papillary thyroid carcinoma.

Authors:  Naoyoshi Onoda; Tetsuro Ishikawa; Hidemi Kawajiri; Tsutomu Takashima; Kosei Hirakawa
Journal:  Surg Today       Date:  2012-06-26       Impact factor: 2.549

Review 2.  Overview of the management of differentiated thyroid cancer.

Authors:  Jyotika K Fernandes; Terry A Day; Mary S Richardson; Anand K Sharma
Journal:  Curr Treat Options Oncol       Date:  2005-01

Review 3.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

4.  Treatment Variation in Older Adults With Differentiated Thyroid Cancer.

Authors:  Whitney Sutton; Joseph K Canner; Dorry L Segev; Martha A Zeiger; Aarti Mathur
Journal:  J Surg Res       Date:  2020-05-21       Impact factor: 2.192

5.  MiR-101 targets USP22 to inhibit the tumorigenesis of papillary thyroid carcinoma.

Authors:  Huadong Zhao; Haili Tang; Qike Huang; Bo Qiu; Xiaomin Liu; Dong Fan; Li Gong; Hang Guo; Chong Chen; Shixiong Lei; Lu Yang; Jianguo Lu; Guoqiang Bao
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

6.  MicroRNA-663 suppresses cell invasion and migration by targeting transforming growth factor beta 1 in papillary thyroid carcinoma.

Authors:  Zhihong Wang; Hao Zhang; Ping Zhang; Wenwu Dong; Liang He
Journal:  Tumour Biol       Date:  2015-12-19

Review 7.  Recurrence of papillary thyroid cancer after optimized surgery.

Authors:  Clive S Grant
Journal:  Gland Surg       Date:  2015-02

8.  Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999-2006.

Authors:  Clive S Grant; John M Stulak; Geoffrey B Thompson; Melanie L Richards; Carl C Reading; Ian D Hay
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

9.  Radio-guided surgery for lymph node recurrences of differentiated thyroid cancer.

Authors:  Massimo Salvatori; Vittoria Rufini; Francesca Reale; Ana Maria Samanes Gajate; Maria Lodovica Maussier; Luca Revelli; Luigi Troncone; Guglielmo Ardito
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

10.  New prognostic scales LAST-1 and LAST-2: supporting prediction and staging of thyroid cancer.

Authors:  Andrzej J Lachinski; Tomasz Stefaniak; Jarek Kobiela; Saxon Connor; Zbigniew Gruca; Zbigniew Sledzinski
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.